ICCC
ICCC
NASDAQ · Biotechnology

Immucell Corp

$6.24
+0.13 (+2.16%)
As of Feb 8, 2:17 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 26.09M 25.83M 25.29M
Net Income 1.24M 1.23M 1.32M
EPS
Profit Margin 4.7% 4.8% 5.2%
Rev Growth +14.0% +0.8% +23.4%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 3.22M 3.09M 3.10M
Total Equity 34.59M 31.72M 30.36M
D/E Ratio 0.09 0.10 0.10
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 1.70M 1.46M 1.67M
Free Cash Flow 1.19M 1.13M 847.0K